TY - JOUR
T1 - Medicine cabinet
T2 - Adjuvant therapy for breast cancer: Who should get what?
AU - Chew, Helen K
PY - 2001
Y1 - 2001
N2 - • Adjuvant tamoxifen citrate benefits all women who have hormone-sensitive breast cancer.• Adjuvant chemotherapy benefits all women who have breast cancer, but the proportional benefits are greater in women younger than 50 years.• The proportional reduction in recurrence and mortality as a result of adjuvant treatment is the same for each patient, but the absolute benefits depend On a patient's risk.• Women with smaller-than-1 cm, node-negative, estrogen receptor-positive breast cancer of low histologic grade have an excellent prognosis without further therapy.• Treatment decisions should be individualized, taking into consideration the clinical evidence and a patient's overall health treatment preferences.
AB - • Adjuvant tamoxifen citrate benefits all women who have hormone-sensitive breast cancer.• Adjuvant chemotherapy benefits all women who have breast cancer, but the proportional benefits are greater in women younger than 50 years.• The proportional reduction in recurrence and mortality as a result of adjuvant treatment is the same for each patient, but the absolute benefits depend On a patient's risk.• Women with smaller-than-1 cm, node-negative, estrogen receptor-positive breast cancer of low histologic grade have an excellent prognosis without further therapy.• Treatment decisions should be individualized, taking into consideration the clinical evidence and a patient's overall health treatment preferences.
UR - http://www.scopus.com/inward/record.url?scp=0035321053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035321053&partnerID=8YFLogxK
U2 - 10.1136/ewjm.174.4.284
DO - 10.1136/ewjm.174.4.284
M3 - Article
C2 - 11290691
AN - SCOPUS:0035321053
VL - 174
SP - 284
EP - 287
JO - Western Journal of Medicine
JF - Western Journal of Medicine
SN - 0093-0415
IS - 4
ER -